Frontiers in Oncology (Nov 2022)
Advances in CAR T cell immunotherapy for paediatric brain tumours
- Padmashree Rao,
- Liam Furst,
- Liam Furst,
- Deborah Meyran,
- Deborah Meyran,
- Deborah Meyran,
- Deborah Meyran,
- Chelsea Mayoh,
- Chelsea Mayoh,
- Paul J. Neeson,
- Paul J. Neeson,
- Rachael Terry,
- Rachael Terry,
- Dong-Anh Khuong-Quang,
- Dong-Anh Khuong-Quang,
- Dong-Anh Khuong-Quang,
- Theo Mantamadiotis,
- Theo Mantamadiotis,
- Paul G. Ekert,
- Paul G. Ekert,
- Paul G. Ekert,
- Paul G. Ekert,
- Paul G. Ekert,
- Paul G. Ekert
Affiliations
- Padmashree Rao
- Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia
- Liam Furst
- Department of Microbiology & Immunology, The University of Melbourne, Victoria, VIC, Australia
- Liam Furst
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, Australia
- Deborah Meyran
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Deborah Meyran
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
- Deborah Meyran
- Université de Paris, Inserm, U976 Human Immunology Pathophysiology Immunotherapy (HIPI) Unit, Institut de Recherche Saint-Louis, Paris, France
- Deborah Meyran
- Children’s Cancer Centre, Royal Children’s Hospital, Parkville, VIC, Australia
- Chelsea Mayoh
- Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia
- Chelsea Mayoh
- School of Women and Children’s Health, University of New South Wales, Randwick, NSW, Australia
- Paul J. Neeson
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Paul J. Neeson
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
- Rachael Terry
- Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia
- Rachael Terry
- School of Women and Children’s Health, University of New South Wales, Randwick, NSW, Australia
- Dong-Anh Khuong-Quang
- Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia
- Dong-Anh Khuong-Quang
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, Australia
- Dong-Anh Khuong-Quang
- Children’s Cancer Centre, Royal Children’s Hospital, Parkville, VIC, Australia
- Theo Mantamadiotis
- Department of Microbiology & Immunology, The University of Melbourne, Victoria, VIC, Australia
- Theo Mantamadiotis
- Department of Surgery Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, Australia
- Paul G. Ekert
- Translational Tumour Biology, Children’s Cancer Institute, Randwick, NSW, Australia
- Paul G. Ekert
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, Australia
- Paul G. Ekert
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Paul G. Ekert
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
- Paul G. Ekert
- School of Women and Children’s Health, University of New South Wales, Randwick, NSW, Australia
- Paul G. Ekert
- 0Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia
- DOI
- https://doi.org/10.3389/fonc.2022.873722
- Journal volume & issue
-
Vol. 12
Abstract
Brain tumours are the most common solid tumour in children and the leading cause of cancer related death in children. Current treatments include surgery, chemotherapy and radiotherapy. The need for aggressive treatment means many survivors are left with permanent severe disability, physical, intellectual and social. Recent progress in immunotherapy, including genetically engineered T cells with chimeric antigen receptors (CARs) for treating cancer, may provide new avenues to improved outcomes for patients with paediatric brain cancer. In this review we discuss advances in CAR T cell immunotherapy, the major CAR T cell targets that are in clinical and pre-clinical development with a focus on paediatric brain tumours, the paediatric brain tumour microenvironment and strategies used to improve CAR T cell therapy for paediatric tumours.
Keywords
